Company intelligence / Profile preview

VITRUVIAE

Ownership: Private
Development stage: Preclinical

Overview

VITRUVIAE’s lead biotherapeutic, VTRU200, targets unique sugar and lipid patterns on cancer cells and viruses that are not present on normal cells. This approach aims to overcome drug resistance by focusing on cellular features that do not mutate or down-regulate like proteins. No clinical trial data has been published yet.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Biotherapeutics targeting sugar and lipid signatures (novel modality distinct from traditional small molecules or mAbs)
Industry: Biotech

Drug pipeline

6 assets

VTRU200

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on VITRUVIAE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VITRUVIAE.

Explore the full profile